1. Home
  2. MEIP vs PRZO Comparison

MEIP vs PRZO Comparison

Compare MEIP & PRZO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MEIP
  • PRZO
  • Stock Information
  • Founded
  • MEIP 2000
  • PRZO 2014
  • Country
  • MEIP United States
  • PRZO Israel
  • Employees
  • MEIP N/A
  • PRZO N/A
  • Industry
  • MEIP Biotechnology: Pharmaceutical Preparations
  • PRZO
  • Sector
  • MEIP Health Care
  • PRZO
  • Exchange
  • MEIP Nasdaq
  • PRZO Nasdaq
  • Market Cap
  • MEIP 17.1M
  • PRZO 13.7M
  • IPO Year
  • MEIP 2003
  • PRZO 2023
  • Fundamental
  • Price
  • MEIP $1.98
  • PRZO $0.60
  • Analyst Decision
  • MEIP Hold
  • PRZO
  • Analyst Count
  • MEIP 1
  • PRZO 0
  • Target Price
  • MEIP N/A
  • PRZO N/A
  • AVG Volume (30 Days)
  • MEIP 11.6K
  • PRZO 214.7K
  • Earning Date
  • MEIP 05-08-2025
  • PRZO 03-21-2025
  • Dividend Yield
  • MEIP N/A
  • PRZO N/A
  • EPS Growth
  • MEIP N/A
  • PRZO N/A
  • EPS
  • MEIP N/A
  • PRZO N/A
  • Revenue
  • MEIP N/A
  • PRZO $932,154.00
  • Revenue This Year
  • MEIP N/A
  • PRZO N/A
  • Revenue Next Year
  • MEIP N/A
  • PRZO N/A
  • P/E Ratio
  • MEIP N/A
  • PRZO N/A
  • Revenue Growth
  • MEIP 33.76
  • PRZO 50.22
  • 52 Week Low
  • MEIP $1.46
  • PRZO $0.49
  • 52 Week High
  • MEIP $4.10
  • PRZO $3.16
  • Technical
  • Relative Strength Index (RSI)
  • MEIP 40.20
  • PRZO 37.62
  • Support Level
  • MEIP $1.86
  • PRZO $0.57
  • Resistance Level
  • MEIP $2.35
  • PRZO $0.65
  • Average True Range (ATR)
  • MEIP 0.16
  • PRZO 0.06
  • MACD
  • MEIP 0.02
  • PRZO 0.01
  • Stochastic Oscillator
  • MEIP 68.42
  • PRZO 38.59

About MEIP MEI Pharma Inc.

MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.

About PRZO ParaZero Technologies Ltd.

ParaZero Technologies Ltd is an aerospace company that is focused on drone safety systems and engaged in the business of designing, developing, and providing autonomous parachute safety systems for commercial drones, also known as unmanned aerial systems. The ParaZero SafeAir system of the comapany applies real-time data analytics to identify and mitigate flight risks autonomously and increase safety for bystanders while protecting the loss of expensive drones, equipment, and payloads.

Share on Social Networks: